Gary Pace Purchases 30,000 Shares of Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary Pace acquired 30,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average price of $1.22 per share, with a total value of $36,600.00. Following the completion of the transaction, the director owned 1,356,376 shares of the company’s stock, valued at approximately $1,654,778.72. This trade represents a 2.26% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Cardiff Oncology Stock Performance

NASDAQ CRDF opened at $1.21 on Monday. The firm’s fifty day moving average price is $1.63 and its two-hundred day moving average price is $1.97. The firm has a market capitalization of $82.73 million, a P/E ratio of -1.81 and a beta of 1.36. Cardiff Oncology, Inc. has a 1 year low of $1.16 and a 1 year high of $4.55.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. On average, research analysts anticipate that Cardiff Oncology, Inc. will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Laurion Capital Management LP raised its stake in shares of Cardiff Oncology by 7.3% in the fourth quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock worth $7,437,000 after purchasing an additional 180,866 shares during the last quarter. Acorn Capital Advisors LLC increased its stake in shares of Cardiff Oncology by 39.3% in the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after purchasing an additional 553,317 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Cardiff Oncology by 7.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after purchasing an additional 104,409 shares in the last quarter. Franklin Resources Inc. bought a new position in Cardiff Oncology in the 4th quarter valued at $3,388,000. Finally, State Street Corp grew its holdings in shares of Cardiff Oncology by 4.0% during the fourth quarter. State Street Corp now owns 1,191,647 shares of the company’s stock worth $3,349,000 after purchasing an additional 45,288 shares in the last quarter. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRDF. Piper Sandler reduced their target price on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. TD Cowen downgraded Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. HC Wainwright cut shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Finally, Craig Hallum lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a report on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $8.75.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.